BALPHARMA Stock Overview
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Bal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹134.50 |
| 52 Week High | ₹157.98 |
| 52 Week Low | ₹88.95 |
| Beta | 0.55 |
| 11 Month Change | 9.72% |
| 3 Month Change | -4.99% |
| 1 Year Change | 27.37% |
| 33 Year Change | 31.48% |
| 5 Year Change | 238.79% |
| Change since IPO | 122.87% |
Recent News & Updates
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet
Sep 19
Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20
Aug 31Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Bal Pharma Limited's (NSE:BALPHARMA) CEO Pay Packet
Sep 19Bal Pharma (NSE:BALPHARMA) Is Increasing Its Dividend To ₹1.20
Aug 31Bal Pharma Limited's (NSE:BALPHARMA) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Aug 27Bal Pharma (NSE:BALPHARMA) Is Paying Out A Larger Dividend Than Last Year
Aug 15Insufficient Growth At Bal Pharma Limited (NSE:BALPHARMA) Hampers Share Price
May 30Does Bal Pharma (NSE:BALPHARMA) Have A Healthy Balance Sheet?
Mar 14Bal Pharma Limited's (NSE:BALPHARMA) 26% Share Price Surge Not Quite Adding Up
Feb 01Bal Pharma Limited's (NSE:BALPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 18Bal Pharma (NSE:BALPHARMA) Is Due To Pay A Dividend Of ₹1.00
Aug 28Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 14Bal Pharma (NSE:BALPHARMA) Is Paying Out A Dividend Of ₹1.00
Aug 17Bal Pharma (NSE:BALPHARMA) Has Announced A Dividend Of ₹1.00
Jul 31Is Bal Pharma (NSE:BALPHARMA) Using Too Much Debt?
Mar 08Bal Pharma (NSE:BALPHARMA) Use Of Debt Could Be Considered Risky
Nov 23Does Bal Pharma Limited (NSE:BALPHARMA) Have A Place In Your Dividend Stock Portfolio?
Aug 10
Should You Buy Bal Pharma Limited (NSE:BALPHARMA) For Its 2.3% Dividend?
Aug 10Shareholder Returns
| BALPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 11.6% | -0.2% | 0.3% |
| 1Y | 27.4% | 40.5% | 27.3% |
Return vs Industry: BALPHARMA underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: BALPHARMA matched the Indian Market which returned 27.3% over the past year.
Price Volatility
| BALPHARMA volatility | |
|---|---|
| BALPHARMA Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: BALPHARMA's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: BALPHARMA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 868 | Shailesh Siroya | www.balpharma.com |
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.
Bal Pharma Limited Fundamentals Summary
| BALPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹2.07b |
| Earnings (TTM) | ₹76.63m |
| Revenue (TTM) | ₹3.25b |
28.2x
P/E Ratio0.7x
P/S RatioIs BALPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BALPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹3.25b |
| Cost of Revenue | ₹1.82b |
| Gross Profit | ₹1.42b |
| Other Expenses | ₹1.35b |
| Earnings | ₹76.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 4.85 |
| Gross Margin | 43.84% |
| Net Profit Margin | 2.36% |
| Debt/Equity Ratio | 225.4% |
How did BALPHARMA perform over the long term?
See historical performance and comparison